Nowadays, the expression of ER, PR, HER2 and Ki67 (monoclonal antibody that measures cell growth fraction) receptors, along with the variable clinicopathological data, such as nodal involvement, tumor size, type, grade of tumor and resection margins are commonly used to choose the treatment and predict the prognosis of the disease.5, 7. Here, ERBB2 is linked to neoplasm.